Should you buy Cardlytics stock now?
No, the technical signal for Cardlytics is currently SELL. Cardlytics trades at $4.18 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.262 with rising momentum (signal: -0.353); RSI is at 45.4 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $10.75 points to 157.2% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Cardlytics stock?
The average analyst price target for Cardlytics is $10.75. The current price is $4.18, which gives an upside of 157.2%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $9.68 and $11.83.
Is Cardlytics a dividend stock?
No, Cardlytics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Cardlytics stock?
Cardlytics is rated as a stock with extreme risk. the annual standard deviation is 143.7%, which classifies the stock as extreme risk.
Is Cardlytics overvalued?
No, Cardlytics is considered undervalued based on the analyst price target (157.2% upside). Cardlytics has the following valuation ratios: a P/S ratio of 0.1, a P/B ratio of 2.1. The analyst price target suggests that the stock is undervalued by 157.2%.
Is Cardlytics overbought?
No, Cardlytics is not overbought. RSI is at 45.4 (neutral zone). The technical indicators show: RSI is at 45.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.4% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Cardlytics earnings report?
The date of the next earnings report for Cardlytics has not been published yet. Check the company's investor calendar for updates.
Is Cardlytics shorted?
Yes, Cardlytics is shorted with 12.0% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Cardlytics stock?
Yes, insiders are net buyers of Cardlytics – they are buying more shares than they are selling. Over the last 3 months, insiders have made 2 purchases and 3 sales. On a net basis, 48,625 $ worth of shares were bought. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 546,075 $ sold. Active buyers include Evans David Thomas. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Cardlytics a good stock?
Based on our total score, Cardlytics is rated as a disastrous stock with a total score of 18 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 47/100, Quality: 7/100, Momentum: 1/100. In addition: analysts see 157.2% upside to the price target; technical signal: Strong Sell. Whether Cardlytics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Cardlytics stock?
The outlook for Cardlytics based on current data: the average analyst price target is $10.75 (+157.2%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Cardlytics stock rising?
Cardlytics is rising right now. The technical indicators show: the price is 4.4% above the 20-day average; short interest is 12.0% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Cardlytics go?
The average analyst price target for Cardlytics is $10.75, which corresponds to a potential gain of 157.2% from the current price of $4.18. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Cardlytics fall?
We lack enough history to give a specific floor for Cardlytics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Cardlytics do?
Cardlytics (cdlx.us) driver en reklameplatform, som primært fungerer i USA og Storbritannien. De tjener penge ved at lade annoncører nå ud til bankkunder direkte gennem deres digitale kanaler. Det gør de via deres Cardlytics-platform, som integrerer reklamer i netbanker, mobil... The company belongs to the Kommunikation sector, more specifically the Advertising Agencies industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Cardlytics as an investment.
Did Cardlytics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Cardlytics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Cardlytics making money or losing money?
No, Cardlytics is currently not making money — the company is losing money with a negative profit margin of -44.8%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Cardlytics go bankrupt?
The bankruptcy risk of Cardlytics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -18.06 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 461% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Cardlytics have a lot of debt?
Yes, Cardlytics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 461%. For the kommunikation sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
